ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

19.95 +0.06 (+0.30%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

19 20 Next >

Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation

December 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

What's Going On With Acadia Pharmaceuticals Stock? ↗

December 13, 2023

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares are trading higher Wednesday after the company won summary judgement in a patent suit regarding its Nuplazid drug. What To Know:

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 13, 2023

Via Benzinga

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Leading the Way in Wednesday Trading Based on Percentage Gain

December 13, 2023

Via Investor Brand Network

Analyst Ratings for ACADIA Pharmaceuticals ↗

December 12, 2023

Via Benzinga

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

November 06, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

October 10, 2023

Via Benzinga

Why Acadia Pharmaceuticals Stock Is Rising Today ↗

October 10, 2023

An analyst upgrade is sparking a rally in the drugmaker's shares today.

Via The Motley Fool

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

December 11, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

November 30, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis

November 27, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

2 Growth Stocks I'd Buy on the Dip ↗

September 30, 2023

These two growth stocks could be worthwhile buy-and-holds.

Via The Motley Fool

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

November 21, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 14, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

Via InvestorPlace

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

November 02, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 02, 2023

Via Benzinga

Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference

October 31, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program

October 23, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023

October 19, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 18, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023 ↗

October 10, 2023

Via Benzinga

Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

October 10, 2023

JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 02, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 28, 2023

Via Benzinga

Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

September 28, 2023

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant...

Via Benzinga

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

September 19, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

August 30, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.